The Effect of Probiotics on the Frequency and Intensity of Migraine Attacks and Intestinal Permeability (Promi2)
Primary Purpose
Migraine
Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
EcologicBarrier
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Migraine
Eligibility Criteria
Inclusion Criteria:
Subjects confirm to have migraine characterized by :
- Recurrent attacks of moderate to severe headaches, often one-sided and pounding, often with nausea and/or vomiting, aggravated by physical activity
- Sensitivity for light or sounds is possible but not exclusive.
- Attacks last for 4 to 72 hours.
- Self-reported frequency of migraine attacks (or days) at least 4 per month
- Fairly predictable/stable pattern of migraine attacks (frequency, duration, intensity)
- Age ≥ 18 years
- Good overall health (self-reported in medical questionnaire)
Exclusion Criteria:
- Migraine patients who suffer from chronic daily migraine/headaches
- Migraine patients who suffer from medication-dependent headaches
- Subjects who suffer from cluster headache or tension-type headaches
- Subjects who used antibiotics up to two months before the start of the study
- Subjects who are unwilling to stop taking probiotics other than study products
- Patients with a chronic use of non steroid anti inflammatory drugs (because of increased gut permeability)
- Patients with inflammatory bowel diseases (because of increased gut permeability)
- Pregnancy or lactation (because of their possible effect on migraine incidence)
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Probiotics
Placebo
Arm Description
EcologicBarrier, 5x10E9 cfu/day
carrier material of Ecologic Barrier, not containing bacterial strains
Outcomes
Primary Outcome Measures
Frequency of migraine attacks
Secondary Outcome Measures
Intestinal permeability
Lactulose/mannitol in urine, zonulin in serum
Inflammation markers.
pro-inflammatory cytokines in serum
Full Information
NCT ID
NCT02342262
First Posted
January 9, 2015
Last Updated
January 14, 2015
Sponsor
Wageningen University
1. Study Identification
Unique Protocol Identification Number
NCT02342262
Brief Title
The Effect of Probiotics on the Frequency and Intensity of Migraine Attacks and Intestinal Permeability
Acronym
Promi2
Official Title
The Effects of Probiotics on the Frequency and Intensity of Migraine Attacks and Intestinal Permeability. A Placebo-controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
January 2015
Overall Recruitment Status
Unknown status
Study Start Date
August 2014 (undefined)
Primary Completion Date
August 2015 (Anticipated)
Study Completion Date
October 2015 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Wageningen University
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
RATIONALE: The prevalence of migraine is higher in patients with various intestinal diseases. An explanation could be that migraine is caused by a 'leaky gut': an increased intestinal permeability that allows food particles to pass the gastrointestinal wall. Probiotics may be able to improve intestinal barrier function.
OBJECTIVE: To test whether probiotics, as adjuvant therapy, can reduce incidence and severity of migraine attacks by reducing intestinal permeability.
STUDY DESIGN: 12-week placebo-controlled randomized double-blind intervention with selected probiotics.
STUDY POPULATION: Adults who experience at least 4 migraine attacks per month. INTERVENTION: Subjects will receive either one daily dose of 2 g of Ecologic® Barrier or 2 grams of the placebo, containing only the carrier material (both provided by Winclove Probiotics).
MAIN STUDY PARAMETERS/ENDPOINTS: Incidence and severity of migraine attacks, measured by diaries and validated headache questionnaires will be measured at baseline and after 4, 8, and 12 weeks of probiotic/placebo administration. Secondary, intestinal permeability will be measured by the lactulose/mannitol absorption test in urine (screening, baseline and 12 weeks) and by fecal zonulin (baseline, 4, 8, and 12 weeks). Inflammation will be assessed from blood C-reactive protein and cytokine concentrations (baseline, 4, 8, and 12 weeks). Fecal samples will also be used for microbial analysis.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Migraine
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
80 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Probiotics
Arm Type
Experimental
Arm Description
EcologicBarrier, 5x10E9 cfu/day
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
carrier material of Ecologic Barrier, not containing bacterial strains
Intervention Type
Dietary Supplement
Intervention Name(s)
EcologicBarrier
Intervention Description
multispecies probiotic product, 2x10-9 cfu/gram
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
similar appearance as the probiotic product, but without bacteria
Primary Outcome Measure Information:
Title
Frequency of migraine attacks
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Intestinal permeability
Description
Lactulose/mannitol in urine, zonulin in serum
Time Frame
12 weeks
Title
Inflammation markers.
Description
pro-inflammatory cytokines in serum
Time Frame
12 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subjects confirm to have migraine characterized by :
Recurrent attacks of moderate to severe headaches, often one-sided and pounding, often with nausea and/or vomiting, aggravated by physical activity
Sensitivity for light or sounds is possible but not exclusive.
Attacks last for 4 to 72 hours.
Self-reported frequency of migraine attacks (or days) at least 4 per month
Fairly predictable/stable pattern of migraine attacks (frequency, duration, intensity)
Age ≥ 18 years
Good overall health (self-reported in medical questionnaire)
Exclusion Criteria:
Migraine patients who suffer from chronic daily migraine/headaches
Migraine patients who suffer from medication-dependent headaches
Subjects who suffer from cluster headache or tension-type headaches
Subjects who used antibiotics up to two months before the start of the study
Subjects who are unwilling to stop taking probiotics other than study products
Patients with a chronic use of non steroid anti inflammatory drugs (because of increased gut permeability)
Patients with inflammatory bowel diseases (because of increased gut permeability)
Pregnancy or lactation (because of their possible effect on migraine incidence)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nicole De Roos, PhD
Organizational Affiliation
Wageningen UR
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
The Effect of Probiotics on the Frequency and Intensity of Migraine Attacks and Intestinal Permeability
We'll reach out to this number within 24 hrs